Intermittent MEK inhibition for the treatment of metastatic uveal melanoma von Khan, Shaheer, Patel, Sapna P, Shoushtari, Alexander N, Ambrosini, Grazia, Cremers, Serge, Lee, Shing, Franks, Lauren, Singh-Kandah, Shahnaz, Hernandez, Susana, Sender, Naomi, Vuolo, Kristina, Nesson, Alexandra, Mundi, Prabhjot, Izar, Benjamin, Schwartz, Gary K, Carvajal, Richard D

Volltext

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy von Khan, Shaheer, Lutzky, Jose, Shoushtari, Alexander N., Jeter, Joanne, Marr, Brian, Olencki, Thomas E., Cebulla, Colleen M., Abdel-Rahman, Mohamed, Harbour, J. William, Sender, Naomi, Nesson, Alexandra, Singh-Kandah, Shahnaz, Hernandez, Susana, King, Jeanelle, Katari, Manpreet S., Dimapanat, Lyssa, Izard, Stephanie, Ambrosini, Grazia, Surriga, Oliver, Rai, Alex J., Chiuzan, Codruta, Schwartz, Gary K., Carvajal, Richard D.

Volltext

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint b... von Manji, Gulam Abbas, May, Michael S., Pellicciotta, Ilenia, Sta Ana, Sarah, Sender, Naomi, Pan, Samuel M, Ross, Isabelle, Hu, Jianhua, Shi, Qian, Raufi, Alexander G

Volltext

A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sa... von Bose, Sminu (Sam), Ge, Liner, Lee, Shing M, Van Tine, Brian Andrew, Agulnik, Mark, Weiss, Mia C., Lacuna, Kristine Peregrino, Sender, Naomi, Sta Ana, Sarah, Hsu, Frank J., Schwartz, Gary K., Ingham, Matthew

Volltext

CTIM-07. A PHASE II, OPEN LABEL, SINGLE ARM STUDY OF NIVOLUMAB FOR RECURRENT OR PROGRESSIVE IDH MUTANT GLIOMAS WITH PRIOR EXPOSURE TO ALKYLATING AGENTS von Yim, Eunji, Donovan, Laura, Bargo, Alicia, Nayak, Lakshmi, Odia, Yazmin, Wong, Eric, Pring, Krystelle, Malig, Mervin, Genfi, Yacha, Wright, Nathaniel, Kesari, Lakshmi, Russ, Alyssa, Chang, Rae, Torres, Denisse, Manjrekar, Kriti Bagri, Ana, Sarah Sta, Sender, Naomi, Mistretta, Suzanne, Iwamoto, Fabio

Volltext

A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma von Ingham, Matthew, Lee, Shing, Van Tine, Brian A, Choy, Edwin, Oza, Jay, Doshi, Sahil, Ge, Liner, Oppelt, Peter, Cote, Gregory, Corgiat, Brian, Sender, Naomi, Sta Ana, Sarah, Panchalingam, Lavan, Petricoin, Emmanuel, Schwartz, Gary K

Volltext

A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAG... von Dallos, Matthew, Pan, Samuel M, Chaimowitz, Matthew, Stein, Mark N., Lim, Emerson A., Hawley, Jessica, Sender, Naomi, Sta Ana, Sarah, Runcie, Karie, Sternberg, Cora N., Bilen, Mehmet Asim, Mille, Patrick Johnston, Kelly, William Kevin, Tagawa, Scott T., Nanus, David M., Drake, Charles G.

Volltext

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy von Khan, Shaheer, Lutzky, Jose, Shoushtari, Alexander Noor, Jeter, Joanne M., Chiuzan, Cody, Sender, Naomi, Blumberg, Lauren Esther, Nesson, Alexandra, Singh-Kandah, Shahnaz V., Hernandez, Susana, Ambrosini, Grazia, Surriga, Oliver, Schwartz, Gary K., Carvajal, Richard D.

Volltext

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath... von Manji, Gulam Abbas, Van Tine, Brian Andrew, Lee, Shing Mirn, Raufi, Alexander, Patwardhan, Parag, Blumberg, Lauren Esther, Sender, Naomi, Wang, Jennifer, Otap, Daniel, Singh-Kandah, Shahnaz V., Do, Khanh Tu, Hirbe, Angela C., Bollag, Gideon, Schwartz, Gary K.

Volltext

Abstract P1-19-32: Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+ metastatic breast cancer (MBC) von Kalinsky, Kevin, Lee, Shing, Tiersten, Amy, Makower, Della F, Cigler, Tessa, Franks, Lauren, Mundi, Prabhjot, Chi, Dow-Chung, Blumberg, Lauren, Sender, Naomi, Galazyn, Magdalena, Hosi, Kristina, Goel, Anupama, Klein, Paula, Andreopoulou, Eleni, Sparano, Joseph, Crew, Katherine D, Califano, Andrea, Silva, Jose, Hershman, Dawn L

Volltext

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychlor... von Manji, Gulam Abbas, Labadie, Brian William, Lee, Shing M, Pellicciotta, Ilenia, Ge, Liner, Sta Ana, Sarah, Sender, Naomi, Ross, Isabelle, Wong, Winston, Raufi, Alexander G

Volltext

Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junct... von Raufi, Alexander Grenander, Lee, Shing, May, Michael, Portillo, Armando Del, Sender, Naomi, Ana, Sarah Sta, Gautier, Katarzyna, Alouani, Emily, Park, Haeseong, Oberstein, Paul, Shah, Manish, Manji, Gulam A.

Volltext

A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors von Stemmer, Salomon M, Benjaminov, Ofer, Silverman, Michael H, Sandler, Uziel, Purim, Ofer, Sender, Naomi, Meir, Chen, Oren-Apoteker, Pnina, Ohana, Joel, Devary, Yoram

Volltext